Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply.
Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
S
S
Ben-Horin
Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
B
0000-0002-6078-2249
B
Ungar
Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France.
X
X
Roblin
D000068879:Adalimumab; D000917:Antibody Formation; D003424:Crohn Disease; D006801:Humans; D007155:Immunologic Factors
D007155:Immunologic Factors; D000068879:Adalimumab